Crystalline P2X3 Modulator Selective Analgesia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pain, particularly those related to P2X3 receptor activity, often have limitations in effectively modulating pain sensation without adverse effects on other physiological responses such as taste and cough.
Innovation Solution
A crystalline form of methyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate, characterized by specific XRPD patterns and thermal analysis profiles, is developed to target P2X3 receptors, offering a potential analgesic effect while minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If P2X3 receptor activity is blocked to achieve analgesic effects, then pain sensation is reduced, but taste response and cough reflex may be adversely affected
Solution Approach 1:
The patent applies local quality by developing a highly selective P2X3 receptor modulator that specifically targets pain-related P2X3 receptors on nociceptive neurons while sparing P2X3 receptors in taste buds and respiratory epithelium. This spatially selective action allows the drug to provide analgesic effects in pain pathways without affecting taste response or cough reflex, thereby resolving the contradiction between analgesic efficacy and preservation of normal physiological functions.
Solution Approach 2:
The patent employs parameter changes by optimizing the chemical structure of the imidazopyridine compound to achieve selective binding kinetics and affinity for P2X3 receptors in different tissue contexts. By adjusting molecular parameters such as substituent groups (e.g., 2,6-difluoro-4-(methylcarbamoyl)phenyl) and stereochemistry (S-enantiomer), the drug achieves differential modulation of P2X3 receptors, providing pain relief while preserving taste and cough functions.
2Reliability
If existing P2X3 modulators are used to treat pain, then analgesic effects are achieved, but side effects such as loss of taste and chronic cough occur
Solution Approach 1:
The invention resolves this contradiction by creating a P2X3 modulator with tissue-specific selectivity. The compound preferentially binds to P2X3 receptors in pain pathways (nociceptive neurons) while having minimal affinity for P2X3 receptors in taste buds and respiratory epithelium. This localized action pattern provides effective pain relief without generating harmful side effects in non-target tissues, thus eliminating the trade-off between analgesic efficacy and side effect profile.
Solution Approach 2:
The patent introduces a structurally optimized imidazopyridine compound as an intermediary that mediates selective P2X3 receptor modulation. The specific molecular structure acts as a selective key that fits P2X3 receptors in pain pathways but not those in taste or respiratory tissues, thereby achieving pain relief without the harmful side effects associated with non-selective P2X3 blockade.
3Ease of manufacture
If non-crystalline or less stable solid forms are used, then manufacturing is simpler, but product stability and bioavailability may be compromised
Solution Approach 1:
The patent applies parameter changes by identifying and characterizing specific crystalline forms (polymorphs) of the P2X3 modulator with optimized physical and chemical properties. By selecting particular crystal structures with defined melting points, solubility characteristics, and stability profiles, the invention achieves an optimal balance between manufacturability and product reliability. The crystalline forms provide enhanced stability and predictable bioavailability while maintaining feasibility for pharmaceutical manufacturing processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline form of the compound effectively modulates P2X3 receptor activity, providing analgesic effects for pain conditions associated with P2X3 receptor activity, such as chronic inflammatory and neuropathic pain, while potentially avoiding side effects like loss of taste and chronic cough.
Implementation Method 1
an X-ray powder diffraction (XRPD) pattern as shown in Figure 1
Implementation Method 2
an X-ray powder diffraction (XRPD) pattern with characteristic peaks
Implementation Method 3
a thermo-gravimetric analysis (TGA) as set forth in Figure 2
Implementation Method 4
a DSC thermogram as set forth in Figure 2
Implementation Method 5
a DSC thermogram with an endotherm having an onset at about 167°C
Data Source
Figure 1~2
Figure 3
Figure 4~5
AI summary
Described herein are crystalline forms of a P2X3 modulator, namely (S)-methyl-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7- methylimidazo[l,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate or a solvate thereof, and use thereof for treating pain, urinary tract disorder, cough, pruritus and endometriosis.